Apadenoson

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameApadenoson
Drug Alias Name阿帕诺生apadenosonum阿帕迪松Stedivaze阿帕地松 +[8] 
ClassificationSmall moleculesDiagnostic agent (In vivo)
Mechanisms of ActionAdenosine A2a receptor agonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsCoronary Artery DiseaseMyocardial IschemiaHeart Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesForest Laboratories Inc
Active IndicationsN/A
Inactive IndicationsCoronary Artery DiseaseMyocardial IschemiaHeart Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG